Unii-Q7SF8H5TF6 | 151069-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Unii-Q7SF8H5TF6
• 英文别名: N-[5,21-dihydroxy-12,14-dioxo-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]formamide
• CAS: 151069-12-4
• 化学式: C₂₇H₂₂N₄O₁₀
• 分子量: 562.5
• InChiKey: WHTCLLAVOBBKHK-ISCYQWKGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  41
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  218
• 氢给体数：
  8
• 氢受体数：
  10

文献信息

• Topoisomerase inhibitors for prevention of restenosis
  申请人：Quanam Medical Corporation

  公开号：US20020004679A1

  公开（公告）日：2002-01-10

  A method of inhibitng cellular proliferation associated with a hyperproliferative condition, such as restenosis, is described. The method includes administering a topoisomerase inhibitor. A stent for local administration of the topoisomerase inhibitor is also described.

  本文描述了一种抑制细胞增殖的方法，该方法与细胞增殖亢进症（如再狭窄）有关。该方法包括施用拓扑异构酶抑制剂。还描述了一种用于局部施用拓扑异构酶抑制剂的支架。
• Liposome-entrapped topoisomerase inhibitors
  申请人：Alza Corporation

  公开号：US20020146450A1

  公开（公告）日：2002-10-10

  A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 &mgr;mole drug per &mgr;mole lipid.

  本文描述了一种用于给药治疗有效剂量的拓扑异构酶抑制剂 I 或拓扑异构酶 I/II 抑制剂的组合物。该组合物包括具有外表面和内表面的脂质体，外表面和内表面限定了一个水性脂质体区室，脂质体由囊泡形成脂质和用亲水性聚合物衍生物化的囊泡形成脂质组成，以在脂质体的内外表面形成亲水性聚合物链涂层。脂质体中包裹的拓扑异构酶抑制剂的浓度至少为每摩尔脂质0.10摩尔药物。
• TOPOISOMERASE INHIBITORS FOR PREVENTION OF RESTENOSIS
  申请人：Quanam Medical Corporation

  公开号：EP1087801B1

  公开（公告）日：2002-01-16
• LIPOSOME-ENTRAPPED TOPOISOMERASE INHIBITORS
  申请人：Alza Corporation

  公开号：EP1121102B1

  公开（公告）日：2003-04-23
• METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS
  申请人：Prolexys Pharmaceuticals, Inc.

  公开号：US20140227221A1

  公开（公告）日：2014-08-14

  Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.